



FOR IMMEDIATE RELEASE

News Release

June 5, 2018

**PreveCeutical Engages Stadnyk & Partners
to Provide Market Awareness and Strategic Advisory Services**

Vancouver, British Columbia: PreveCeutical Medical Inc. (the “Company” or “PreveCeutical”) (CSE: PREV, OTCQB: PRVCF, FSE: 18H), announces that it has entered into an agreement with Stadnyk & Partners, whereby it has agreed to engage Stadnyk & Partners to provide strategic advisory services to the Company.

The agreement provides that Stadnyk & Partners will provide market awareness services to the Company during the term of the agreement, for which the Company will issue 2 million stock options to Stadnyk & Partners, each of which options will be exercisable to acquire one common share in the capital of the Company for \$0.08 per share for a period of 24 months. The initial term of the agreement is 12 months, subject to renewal by mutual agreement of the parties.

Stadnyk & Partners will provide strategic finance, M&A and capital markets advisory services to the Company to assist it in achieving its business growth goals during the term of the agreement, for which the Company will issue 3 million stock options to Stadnyk & Partner, exercisable on the terms set out above.

Founder, David Stadnyk, has more than 30 years as a leader in the public company space and has successfully initiated equity capital fundraising efforts in excess of \$500 million. As an entrepreneur he has founded both private and public companies including, Pharmaxis, Eurpraxia Pharmaceuticals, Supreme Cannabis Company, Friday Night Inc., and M Pharmaceutical Inc. among others.

About Stadnyk & Partners

Stadnyk & Partners is an international firm with offices in Vancouver, Toronto and New York City, but prides itself on the strength of its long-term relationships and the direct, personal involvement of its leadership team in each deal. Stadnyk & Partners’ founder, David Stadnyk, has more than 30 years of investment experience as a leader in the public company space. Mr. Stadnyk’s vision and ability to innovate has resulted in a remarkable track record, delivering substantial value to shareholders. As an entrepreneur, he has founded both private and public companies in the cannabis, resource, pharmaceutical and sports and entertainment spaces. Mr. Stadnyk identifies investment opportunities, develops the strategic direction for each company and establishes specialized teams to maximize results.

About PreveCeutical

PreveCeutical is a health sciences company that develops innovative options for preventive and curative therapies utilizing organic and nature identical products.

PreveCeutical aims to be a leader in preventive health sciences and currently has five research and development programs, including: dual gene therapy for curative and prevention therapies for diabetes and obesity; the Sol-gel Program; Nature Identical™ peptides for treatment of various ailments; non-addictive analgesic peptides as a replacement to the highly addictive analgesics such as morphine, fentanyl and oxycodone; and a therapeutic product for treating athletes who suffer from concussions (mild traumatic brain injury).

PreveCeutical sells CELLB9®, an Immune System Booster. CELLB9® is an oral solution containing polarized and potentiated essential minerals extracted from a novel peptide obtained from Caribbean Blue Scorpion venom. This product is available on the Company's website. For more information about PreveCeutical, please visit www.PreveCeutical.com, follow us on Twitter: <http://twitter.com/PreveCeuticals> and Facebook: www.facebook.com/PreveCeutical.

On Behalf of the Board of Directors

"Stephen Van Deventer"
Chairman, CEO and President

For further information, please contact:

Deanna Kress
Director of Corporate Communications & Investor Relations
+1-778-999-6063
deanna@PreveCeutical.com

Forward-Looking Statements:

This news release contains forward-looking statements and forward-looking information (collectively, "forward-looking statements") within the meaning of applicable Canadian and U.S. securities legislation, including the United States *Private Securities Litigation Reform Act of 1995*. All statements in this news release that are not purely historical are forward-looking statements and include statements regarding beliefs, plans, expectations and orientations regarding the future including, without limitation, the expected duration of the investor relations and advisory services agreement and any expected benefit to the Company thereunder, the Company's anticipated business plans and its prospect of success in executing its proposed plans. Often, but not always, forward-looking statements can be identified by words such as "plans", "expects", "may", "intends", "anticipates", "believes", "proposes" or variations of such words including negative variations thereof and phrases that refer to certain actions, events or results that may, could, would, might or will occur or be taken or achieved. Actual results could differ from those projected in any forward-looking statements due to numerous factors including, but not limited to, the state of the financial markets for the Company's equity securities and the inability of the Company to execute its proposed business plans and obtain the financing required to carry out its planned future activities. Other factors such as general economic, market or business conditions or changes in laws, regulations and policies affecting the biotechnology or pharmaceutical industry, may also adversely affect the future results or performance of the Company. These forward-looking statements are made as of the date of this news release and, unless required by applicable law, the Company assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in these forward-looking statements. Although the Company believes that the statements, beliefs, plans, expectations, and intentions contained in this news release are reasonable, there can be no assurance that those statements, beliefs, plans, expectations, or intentions will prove to be accurate. Readers should consider all of the information set forth herein and should also refer to other periodic reports provided by the Company from time-

to-time. These reports and the Company's filings are available at www.sedar.com.

Readers are cautioned that forward-looking statements are not guarantees of future performance or events and, accordingly, are cautioned not to put undue reliance on forward-looking statements due to the inherent uncertainty of such statements.